# DISCUSSION PAPERS IN ECONOMICS

Working Paper No. 02-20

## Modeling and Estimating Preferences Over Treatment Programs for Depression

Jennifer Thacher
Department of Economics, University of Colorado at Boulder
Boulder, Colorado

October 2002

**Center for Economic Analysis**
Department of Economics

University of Colorado at Boulder
Boulder, Colorado 80309

Modeling Tmegectiveness, money costs, time costs, use of psychotherapy, use of antidepre

After the individuals chooses their preferred alternative, they are ask

treatment option is preferred to remaining depressed. Each respondent

pairs. The data is used to estimate 3 random-utility models. Prelim

The value of consuming market goods is less when one is depressed. T

willingness-to-pay, $WTP$, to eliminate one's depression and willingnes

$WTP$ to avoid sexual and weight-gain side effects can be high but varie

uals as a function of observable characteristics. (3) At sufficiently high

side effects, some individuals will prefer to remain.

utility framework is used to mo

as a function of the characteri

Characteristics of treatment inc

anti-depressants, and sexual and

characteristics, including cost, i

and previous experience with si

of market goods is affected by on

to eliminate or reduce depressi

effects. Preliminary findings in

depressed. This drives a wedge

to avoid sexual and weight-gain

function of observable character

some individuals will prefer to r

*Department of Economics, CB 256; Boulder CO 80309-0256; Jennifer.Thacher@colorado.edu

1

The data used to estimate the models come from a choice question survey administered to depressed patients at a mental health facility in Colorado.[1] A choice question asks an individual to choose her preferred alternative from some discrete number of alternatives, each described in terms of the levels of a common and finite site of characteristics. Figure 1 is an example choice question.

| | Alternative A | Alternative B |
|---|---|---|
| **If you had to choose, would you prefer Alternative A or Alternative B?** | | |
| Effectiveness | Not Depressed | Not Depressed |
| Hours of psychotherapy per month | 6 hours | 4 hours |
| Use of anti-depressants | Yes | Yes |
| Your monthly cost for treatment | $300 | $300 |

Figure 1: Example Choice Question

In this study, the individual is presented with five pairs of treatment programs and chooses her preferred alternative in each pair. Each treatment is described in terms of its money cost, hours of psychotherapy, use of anti-depressants, and side effects experienced if the treatment includes anti-

responses to value, in dollars, treatment programs for depression.

Responses to choice questions are stated-preference data (SP data) in contrast to revealed preference data (RP data). RP data consists of observed behavior and choices that can be used to infer values. SP data are statements about the respondents' preferences. Existing RP data has limited capabilities to estimate preferences over health treatment programs. Reasons include: the widespread presence of insurance within the US and universal health care systems outside the US, which obscures the supply demand relationship; much of the decision-making is done by the clinician; and the non-participation of certain populations in the health care market (Johnson et al, 2000). For these reasons, market prices are unobserved or do not reflect the full values of the services. In addition, since the researcher cannot control the independent variables in a revealed preference study, the researcher may be unable to determine the relative importance of variables because of correlations.[3] SP studies, such as choice

this new drug. This procedure is repeated for each side effect. The occurrence of multiple side effects at the same time is not considered. A lower and upper bound for WTP for multiple risk reduction is estimated. The upper bound is calculated as the average over all respondents of the sum of the WTP for each individual side effect. The lower bound on WTP is calculated by identifying for each individual the side effect over which she had the greatest WTP and then averaging over all individuals. On average, individuals were willing to pay the most ($Can21.9 per month) to reduce the risk of blurred vision by 5% and the lowest ($Can11.4 per month) to reduce the risk of dry mouth by 25%.

patients took the Shedler QuickPsychoDiagnostics (QPD) survey on a handheld device (Schedler et al, 2000). The QPD is an initial evaluation tool that provides, among other things, a depression score for each patient, a listing of depression symptoms, and any co-morbidities, such as anxiety or substance

ability level is grade six, as assessed by the Flesch-K

From this, 16 choice sets were selected for the final design. The final design was divided into four blocks of four choice sets, resulting in four di

are on average rated as Pretty Important. Number of therapy hours is rated as Somewhat Important. While the average rankings are not significantly di erent from each other, they vary significantly across individuals.

Forty five percent of respondents would need to take time o work in order to attend therapy sessions while 31% would need to arrange for child care. The most commonly picked descriptions of therapy are: helpful, chance to deal with things, self-exploration, and problem-solving. The most commonly picked descriptions of anti-depressants are: helpful, embarrassing, and common method.

## 2.1   Summary Statistics

Table 2 shows the share of times that the chosen alternative had certain attributes.  For example, 61% of the time, individuals choose a treatment plan that eliminates their depression over a treatment plan that merely reduces it. Table 3 shows how respondents answer the follow-up question on the basis of treatment. In 89% of the follow-up choices, treatment, which either eliminated or reduced depression, is chosen.

|  | Frequency | Percentage |
|---|---|---|
| **Eliminated Depression** | 114 | 61% |
| **Had Lower Weight Gain Side Effect** | 262 | 70% |
| **No Orgasm Side Effect Does Not Occur** | 149 | 65% |
| **No Sex Side Effect Does Not Occur** | 123 | 51% |
| **Involved Therapy** [a] | 121 | 62% |
| Use of Anti-Depressants [a] | 43 | 40% |

a both therapy and anti-depressants  Treatment program could includ

Table 2: What Share of Times did the Chosen Alternative Have Certain Attributes?

| Follow-up Choice |  |  |  |  |
|---|---|---|---|---|
|  | 237 | 51% | Chose Not Depressed over Current Depression |
|  | 29 | 6% | Chose Current depression over Not Depressed |
| pression | 134 | 28% | Chose Some Depressive Symptoms over Current De |
| mptoms | 21 | 4% | Chose Current Depression over Same Depressive Sy |

Table 3: Treatment Choices in Follow-up Question

As noted earlier, after the set of choice questions, respondents use a five point scale to identify the importance of each attribute in answering the choice questions. In order to identify potential sources of heterogeneity, OLS regressions were run on how respondents ranked the importance of each attribute as a function of personal characteristics. However, when an individual answers that an attribute was important to him, it is not clear whether it was important in a positive or negative way. Therefore, the expected sign of the preference parameter may be positive or negative.

These regressions show that respondents who are older, more highly educated, work more hours per week, or who have no previous treatment experience feel that treatment e ectiveness is relatively more important.  There is an inverse relationship between income, education, weekly work hours and how individuals rank the importance of the cost. These explanatory variables are most likely highly correlated.

9

In general, how individuals feel about the side effects is a function of gender and age. For example, compared to men, women tended to rate the weight gain side e

$$+ (\check{z}_{no}N\,O_k + \check{z}_{ns}N\,S_k$$

probability

imply an estimated maximum willingness-to-pay, WTP, of $1471 per month to eliminate depression by therapy alone and $810 to reduce depression through the same method, a ratio of almost two to one.[18] In interpreting these results, it should be recalled that these estimates do not allow for any individual heterogeneity in preferences. These estimates are an average over all income levels. Furthermore, these amounts would be paid a limited amount of time, while the costs of not treating depression can increase proportionately over time.

Ignoring monetary costs, one's utility if treated solely with anti-depressants is

$$U_i = 2.29Ad + (-.58NO - .27NS - 1.08WG) + \epsilon_i \tag{6}$$

On average, estimated WTP to eliminate depression through anti-depressants only is approximately $300 less than the WTP to achieve the same outcome through therapy alone. If treatment combines both therapy and anti-depressants,

$$
\begin{aligned}
U_{ik} = {} & .02[T_i \cdot H_k] \\
& + 2.67Bt_k \\
& (-.58NO_k - .27NS_k - 1.08WG_k) + \epsilon_{ik}
\end{aligned}
$$

The parameter estimate on $Bt_k$ is not significantly different from the parameter estimate on NDth but it is significantly larger than the parameter estimate on DSth. Estimated WTP to eliminate depression with both therapy and anti-depressants is $1350.

Similar to Revicki and Wood (1998) and O'Brien et al (1995), the results suggest that individuals view some side effects as being worse than others. By assumption, the impact of side effects from anti-depressants is the same independent of whether one receives therapy. Estimated WTP is $548 per month to avoid weight gain[19], $295 to avoid the no-orgasm side effect, and $138 to avoid the no sex-drive side e

## 3.2  Model 2: Allowing the Value of Goods to Depend on Emotional state

Model 2 generalizes Model 1 by allowing the value of market goods to di er depending on one's emotional state. The conjecture is that individuals get greater pleasure from the consumption of goods when they are not depressed. Assume

$$
\begin{aligned}
U_{ik} = & \ (\check{Z}_m + \check{Z}_{md}D_k + \check{Z}_{mds}DS_k)(Y_i \cdot Cost_k) + \check{Z}_t[T_i \cdot H_k] \qquad (7)\\
& + \check{z}_{ndth}NDth_k + \check{z}_{dsth}DSth_k \\
& + \check{z}_{ad}Ad_k + \check{z}_{bt}Bt_k \\
& + \check{z}_{no}NO_k + \check{z}_{ns}NS_k + \check{z}_{wg}WG_k \\
& + \text{\textcent}_k
\end{aligned}
$$

where

$$
\begin{aligned}
D_k &= \text{Emotional state is depressed (1= Yes, 0= No)}\\
DS_k &= \text{Emotional state is some depressive symptoms (1= Yes, 0= No)}
\end{aligned}
$$

Equation 7 is identical to Equation 2 except $\check{Z}_m$ is generalized to $(\check{Z}_m + \check{Z}_{md}D_k + \check{Z}_{mds}DS_k)$; that is, this specification allows the marginal utility of money to di er as a function of the three emotional states. Assuming Equation 7, income does not drop out of the choice probabilities. Income e ects are implied in the sense that the alternative chosen in the choice pairs a ects one's emotional state, which in turn a ects the value one places on market goods. Table 5 shows the parameter estimates for this model.

| Parameter | | Estimate | Est./s.e. | Prob. |
|---|---|---|---|---|
| MU of Income= - (money cost parameter) | $\alpha_m$ | 2.21 | 2.5500 | 0.0054 |
| Reduction in MU of Income if Depressed | $\alpha_{md}$ | -0.36 | -4.5300 | 0.0000 |
| Reduction in MU of Income if Depressive Symptoms | $\alpha_{mds}$ | -0.08 | -1.9200 | 0.0274 |
| MU of Time= (time cost parameter) | $\alpha_t$ | -0.04 | 0.7580 | 0.2242 |

Table 5: Model 2 Maximum Likelihood Parameter Estimates

The mean log likelihood is -0.89. Model 2 correctly predicts 70% of the AB choices, 89% of the follow-up choices, and 63% of both choices. A likelihood ratio test was performed to test the hypothesis that $\check{Z}_{mds} = \check{Z}_{md} = 0$. This hypothesis was rejected at the 1% level. Model 2 statistically dominates Model 1.

The conjecture is confirmed. The estimated marginal utility of money is 2.21 if the individual is not depressed, 2.13 (2.21 · .08) if the individual has some depressive symptoms and 1.84 if the individual is depressed. Consumption loses 17% of its value when an individual is depressed.

Given that Model 2 incorporates income e ects, calculation of WTP is more complicated and WTP no longer equals WTA.[20] Consider an individual's WTP to eliminate her depression through the use of therapy alone. Ignoring the insignificant time costs associated with therapy and assuming zero cost for treatment, [21]

$$WTP = \cdot \frac{\check{Z}_{md}}{\check{Z}_m} Y_i + \frac{\check{Z}_{NDth}}{\check{Z}_m}$$

(8)

Equation 8 shows that eliminating depression has two e ects on an individual's utility level. The first term is an income e ect. Eliminating depression increases

| Income | WTP | WTA |
|--------|-------|-------|
| $30,000 | $1,128 | $1,351 |
| $55,000 | $1,471 | $1,763 |
| $90,000 | $1,953 | $2,351 |

Table 6: Estimated WTP vs WTA by Income Level (when depression can be eliminated by therapy alone)

Table 9 shows the average WTP and WTA for individuals in the sample when depression could be eliminated using therapy .

|  | Average | Std Dev | Min | Max |
|-----|---------|---------|------|--------|
| WTP | $1,458 | $422 | $783 | $2,780 |
| WTA | $1,747 | $506 | $939 | $3,330 |

Table 7: Sample WTP vs WTA (when depression can be eliminated with therapy alone)

Assuming no side effects, the estimated average WTP to eliminate depression with only anti-depressants is $1206 per month; estimated WTA is $1444. Generalizing the model to allow the value of goods to depend on one's emotional state increases the WTP and WTA associated with successful treatment of depression. Model 1 was underestimating WTP for these scenarios.

In Model 2, estimated WTP to avoid side effects and WTA side effects depends on the reference point (depressed, some depressive symptoms and not depressed). For example one could ask how much an individual on anti-depressants who is currently experiencing side effects but no depression would pay per month to eliminate those side effects. This amount is calculated using the individual's marginal utility of money when she is not depressed. For this scenario, estimated WTP to avoid weight gain is $484 per month. It is $258 to avoid the no-orgasm side effect and $156 to avoid the no sex-drive side effect. WTA = WTP, as we are assuming the same emotional state in both scenarios.

Alternatively, one could use the model to estimate what a depressed individual would pay per month to not gain weight. To value that scenario, one would use the marginal utility of money that applies when the individual is depressed. For the weight gain, this estimated WTP is $580; the individual is willing to pay more when depressed because money is worth less when one is depressed.

Using anti-depressants alone or in combination with therapy to eliminate depression when it results in all three side effects has a negative but not significant impact on utility. The combined impact of the side effects cancels out the gain from eliminating the depression.

Summarizing, Model 1 and 2 give different results and Model 2 is statistically preferred. Both Model 1 and Model 2 are highly restrictive in that, conditional on emotional state, both assume everyone has the same preferences over depression treatment programs. Model 2 suggests that with side effects, treatment with anti-depressants will be an improvement for some and a (non-significant) deterioration for others. Previous studies have found a similar result: severe depression is considered worse than an improved emotional state combined with medication side effects (Revicki and Wood, 1998). Model 3 generalizes Model 2 by allowing preferences for treatment to vary as a function of observable characteristics of the individual. In this case, when certain personal characteristics are accounted for, some individuals do not rank the elimination of their depression as an improvement and in certain extreme cases view the treatment and improved emotional state as worse than their current depression.

## 3.3  Model 3: Preference Heterogeneity

Model 3 generalizes Model 2 by making parameters a function of characteristics of the individual. We investigated the impact of the following individual characteristics: household income, gender, education level, the individual's current level of depression as rated by the clinician, race/ethnicity, age, previous experience with the side e

For example, the impact of weight gain side-effect, $(\check{z}_{wg} + \check{z}_{wgf}F_i + \check{z}_{wgpv}Pv_i + \check{z}_{wsk}Sk_i)$ is a function of gender, previous experience with this side effect, and whether one is underweight according

is, individuals with more income have a higher WTP to eliminate depression and side eﬀects. Simply because of di

.13NS $\cdot$ 1.68WG + $\epsilon_i$. She would rather remain depressed than experience the weight-gain side effect, and is close to indifferent between remaining depressed and not being depressed but experiencing the no orgasm side effect. She is affected little by the no sex drive side effect. Alternatively, if the same female was moderately depressed, $U_i$ = 1.62 $\cdot$ 1.02NO $\cdot$ .13NS $\cdot$ 1.68WG + $\epsilon_i$, she is indifferent being not depressed with the weight gain or remaining depressed, but she would not accept both the weight gain and no orgasm side effects. In the case of severe depression, she is indifferent between all three side effects and eliminating her depression. The result that WTP to avoid side effects varies with income level and demographic characteristics is different from O'Brien et al (1995).

## 4  Extensions

As noted earlier, this paper remains a work in progress. The primary work to be done deals with exploring additional types of preference heterogeneity. Model 3 will be expanded to deal with other potential sources of preference heterogeneity. Additional examination of how individuals answered attitudinal questions will be used to help identify and model this heterogeneity. In addition, this paper will explore how latent class models and cluster analysis can be used to model heterogeneity.

## References

[1] Adamowicz W; Louviere J; Swait J. Introduction to attribute-based stated choice methods. NOAA REPORT, 1998.

[2] Adamowicz, W; Louviere J; Williams M. Combining revealed and stated preference methods for valuing environmental amenities. JOURNAL OF ENVIRONMENTAL ECONOMICS AND MAN-AGEMENT 1994, Vol 26, pp 271-292.

[8] Bryan S; Buxton M; Sheldon R; Grant A. Magnetic resonance imaging for the investigation of knee injuries: An investigation of preferences. HEALTH ECONOMICS 1998, Vol 7, Iss 7, pp 595-603

[9] Bryan S; Gold L; Sheldon R; Buxton M. Preference measurement using conjoint methods: An empirical investigation of reliability. HEALTH ECONOMICS 2000, Vol 9, Iss 5, pp 385-395

[10] Dwight-Johnson M; Sherbourned CD; Liao D; Wells KB. Treatment Preferences Among Depressed Primary Care Patients. JOURNAL OF GENERAL INTERNAL MEDICINE, 2000. Vol 15, pp. 527-534.

[11] Farrar S; Ryan M; Ross D; Ludbrook A. Using discrete choice modeling in priority setting: an application to clinical service developments. SOCIAL SCIENCE & MEDICINE 2000, Vol 50, Iss 1, pp 63-75.

[12] Green C; Brazier J; Deverill M. Valuing health-related quality of life: a review of health state valuation techniques. PHARMACOEONOMICS 2000 Vol 17, Iss 2, pp 151-165.

[13] Green P; Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. JOURNAL OF MARKETING 1990, Vol 3.

[14] Hakim Z; Pathak DS. Modelling the EuroQol data: A comparison of discrete choice conjoint and conditional preference modeling. HEALTH ECONOMICS 1999, Vol 8, Iss 2, pp 103-116.

[15] Hensher D. Stated preference analysis of travel choices: the state of practice. TRANSPORTATION 1994, Vol 21, pp 107-133.

[16] Huber J; Zwerina K. The importance of utility balance in e cient choice designs. JOURNAL OF MARKETING RESEARCH 1996, Vol 33, pp. 307-317.

[17] Johnson F; Ruby M; Desvouges W; King J. Using stated preferences and health-state classifications to estimate the value of health e ects of air pollution: final report. TER Technical Working Paper No. T-9807, Triangle Economic Research: Durham, NC, 1998.

[18] Johnson F; Banzhaf M; Desvousges W. Willingness to pay for improved respiratory and cardiovas-

[23] Louviere J. Experimental choice analysis: introduction and overview. JOURNAL OF BUSINESS RESEARCH 1992, Vol 24: 89-95.

[24] Mortimer R. Demand for prescription drugs: the e ects of managed care. University of California, Berkeley. Dissertation. 1998.

[25] Magat W; Viscusi W.; Huber J. Paired comparison and contingent valuation approaches to morbidity risk valuation. JOURNAL OF ENVIRONMENTAL ECONOMICS AND MANAGEMENT 1988, Vol 15, pp 395-411.

[26] Mathews K; Desvousges W; Johnson F; Ruby M. Using economic models to inform restoration decisions: the lavaca bay, Texas experience", TER technical report prepared for presentation at the Conference on Restoration of Lost Human Uses of the Environment, Washington, DC. May 7-8 1997.

[27] McKenzie L; Cairns J; Osman L. Symptom-based outcome measures for asthma: the use of discrete choice methods to assess patient preferences. HEALTH POLICY 2001, Vol 57, Iss 3, pp 193-204.

ct

[35] Revicki D; Shakespeare A; Kind P. Preferences for schizophrenia-related health states: A comparison of patients, caregivers, and psychiatrists. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 1996, Vol 11, Iss 2, pp 101-108.

[36] Revicki D; Wood M. Patient-Assigned Health State Utilities for Depression-Related Outcomes:: Di erences by Depression Severity and Antidepressant Medications. JOURNAL OF AFFECTIVE DISORDERS, 1998. Vol 48. pp. 25-36.

[37] Ryan M; Bate A. Testing the assumptions of rationality, continuity and symmetry when applying discrete choice experiments in health care. APPLIED ECONOMICS LETTERS 2001, Vol 8, Iss 1, pp 59-63

[38] Ryan M; Bate A; Eastmond CJ; Ludbrook A. Use of discrete choice experiments to elicit preferences. QUALITY IN HEALTH CARE 2001, Vol 10, pp I55-I60

[39] Ryan M; Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. HEALTH ECONOMICS 1997, Vol 6, Iss 3, pp 261-273 13

[40] Ryan M; McIntosh E; Dean T; Old P. Trade-o s between location and waiting times in the provision of health care: the case of elective surgery on

[48] Wells K; Sherbourne C.  Functioning and utility for current health of patients with depression or chronic medical conditions in managed primary care practices.  ARCH GEN PSYCHIATRY 1999, Vol 56, pp. 897-904.

$$P_{ijA\cap A} \quad = \quad P(U_{ijA} \geq U_{ijB} \cap U_{ijA} \geq U_{ijNT})$$

$$= \quad P[(V_{ijA} + \epsilon_{jA} \geqslant V_{ijB} + \epsilon_{jB}) \cap (V_{ijA} + \epsilon_{jA} \geqslant V_{ijNT} + \epsilon_{jNT})]$$

$$= \quad P[(\epsilon_{jB} \leq V_{ijA} - V_{ijB} + \epsilon_{jA}) \cap (\epsilon_{jNT} \leq V_{ijA} - V_{ijNT} + \epsilon_{jA})]$$

By assumption, the error terms $\epsilon_{jA}, \epsilon_{jB}, \epsilon_{jNT}$, are independent draws from the extreme value distribution. Given this asumption, we can rewrite the above as

$$P_{ijA\cap A} = \int_{-\infty}^{\infty} \left[ \int_{-\infty}^{V_{ijA}-V_{ijB}+\epsilon_{jA}} f(\epsilon_{jB}) d\epsilon_{jB} \right] \left[ \int_{-\infty}^{V_{ijA}-V_{ijNT}+\epsilon_{jA}} f(\epsilon_{jNT}) d\epsilon_{jNT} \right] f(\epsilon_{jA}) d\epsilon_{jA}$$

$$= \int_{-\infty}^{\infty} [F(\epsilon_{jB})]\Big|_{-\infty}^{V_{ijA}-V_{ijB}+\epsilon_{jA}} [F(\epsilon_{jNT})]\Big|_{-\infty}^{V_{ijA}-V_{ijNT}+\epsilon_{jA}} f(\epsilon_{jA}) d\epsilon_{jA}$$

For the extreme value distribution, $f(\epsilon) = \exp(-\epsilon - e^{-\epsilon})$ and $F(\epsilon) = \exp(-e^{-\epsilon})$. Substituting,

$$P_{ijA\cap A} = \int_{-\infty}^{\infty} [\exp(-e^{-\epsilon_{jB}})]\Big|_{-\infty}^{V_{ijA}-V_{ijB}+\epsilon_{jA}} [\exp(-e^{-\epsilon_{jNT}})]\Big|_{-\infty}^{V_{ijA}-V_{ijNT}+\epsilon_{jA}} \exp(-\epsilon_{jA} - e^{-\epsilon_{jA}}) d\epsilon_{jA}$$

$$= \int_{-\infty}^{\infty} \left[ \exp(-e^{V_{ijB}-V_{ijA}-\epsilon_{jA}}) \right] \left[ \exp(-e^{V_{ijNT}-V_{ijA}-\epsilon_{jA}}) \right] \exp(-\epsilon_{jA} - e^{-\epsilon_{jA}}) d\epsilon_{jA}$$

$$= \int_{-\infty}^{\infty} \exp\left[ -e^{V_{ijB}-V_{ijA}-\epsilon_{jA}} - e^{V_{ijNT}-V_{ijA}} \right.$$

and

$$P_{ijNT} = \frac{e^{V_{ijNT}}}{e^{V_{ijA}} + e^{V_{ijB}} + e^{V_{ijNT}}}$$

# 6 Appendix 2

| Effectiveness Attribute | | |
|---|---|---|
| Level | Frequency | Percent |
| Some Depressive Symptoms | 365 | 36% |
| Not Depressed | 641 | 64% |

| Therapy Hours Attribute | | |
|---|---|---|
| Level | Frequency | Percent |

| Sex Drive Side Effect Attribute | | |
| --- | --- | --- |
| Level | Frequency | Percent |
| No Sex Drive Side E ect Does Not Occur | 680 | 68% |
| No Sex Drive Side E ect Occurs | 326 | 32% |

| Weight Gain Side Effect Attribute | | |
| --- | --- | --- |
| Level | Frequency | Percent |
| No Weight Gain | 521 | 52% |
| 5% Weight Gain | 244 | 24% |
| 10% Weight Gain | 130 | 13% |
| 15% Weight Gain | 111 | 11% |

| | Not Depressed | Therapy Hours | Cost | Anti-Depressants | No Orgasm | No Sex Drive | Weight Gain |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Not Depressed | 1.00 | 0.18 | 0.23 | 0.07 | 0.20 | 0.27 | -0.09 |
| Therapy Hours | 0.18 | 1.00 | -0.02 | -0.09 | -0.24 | 0.09 | -0.44 |
| Cost | 0.23 | -0.02 | 1.00 | -0.12 | -0.09 | -0.35 | -0.32 |
| Anti-Depressants | 0.07 | -0.09 | -0.12 | 1.00 | 0.05 | 0.30 | 0.14 |
| No Orgasm | 0.20 | -0.24 | -0.09 | 0.05 | 1.00 | 0.00 | -0.11 |
| No Sex Drive | 0.27 | 0.09 | -0.35 | 0.30 | 0.00 | 1.00 | 0.02 |
| Weight Gain | -0.09 | -0.44 | -0.32 | 0.14 | -0.11 | 0.02 | 1.00 |

Design Correlation between Attribute Di erences